Skip to main content
Premium Trial:

Request an Annual Quote

Micromet Licenses Single-Chain Antibody Technology to EvoGenix

NEW YORK, Dec.23 (GenomeWeb News) - Micromet of Munichhas licensed its single-chain antibody technology to Sydney-based EvoGenix, the companies said today.


The technology is owned by both Micromet and Enzon Pharmaceuticals. Under the agreement, EvoGenix will apply the technology, in combination with its own, to generate and optimize antibodies for use in diagnostic or therapeutic products.


Micromet will receive an upfront payment, as well as annual maintenance and sublicensing fees, which it will share with Enzon.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.